Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
Blueprint Medicines reports Q1 EPS ($1.72), consensus ($1.87) » 07:39
04/29/21
04/29
07:39
04/29/21
07:39
BPMC

Blueprint Medicines

$97.26 /

-1.91 (-1.93%)

Reports Q1 revenue…

Reports Q1 revenue $21.58M, consensus $17.25M. "In recent months, we made significant progress toward achieving our key 2021 portfolio goals, illustrating our clinical leadership in systemic mastocytosis and the rapid advancement of our next wave of therapeutic candidates with first- or best-in-class potential," said CEO Jeff Albers. "With a potential U.S. approval for AYVAKIT in advanced systemic mastocytosis in the second quarter, we are looking forward to welcoming a new era of precision medicines care for people living with this debilitating disease. In parallel, we are initiating multiple clinical trials across our pipeline, beginning with the Phase 1 trial of BLU-945 and Phase 2/3 HARBOR trial of BLU-263, as we continue to translate our research productivity and precision therapy expertise to address patient need across cancers and hematologic malignancies. Taken together, these accomplishments position Blueprint Medicines to help an increasing number of patients globally as we advance our robust portfolio."

ShowHide Related Items >><<
BPMC Blueprint Medicines
$97.26 /

-1.91 (-1.93%)

BPMC Blueprint Medicines
$97.26 /

-1.91 (-1.93%)

04/13/21 Wedbush
Blueprint Medicines price target raised to $136 from $119 at Wedbush
04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
BPMC Blueprint Medicines
$97.26 /

-1.91 (-1.93%)

Recommendations
Blueprint Medicines price target raised to $136 from $119 at Wedbush » 08:09
04/13/21
04/13
08:09
04/13/21
08:09
BPMC

Blueprint Medicines

$92.68 /

-1.73 (-1.83%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos raised the firm's price target on Blueprint Medicines to $136 from $119 and keeps an Outperform rating on the shares. The analyst notes the company presented a broad update of its pipeline at this week's American Association for Cancer Research virtual meeting, reiterating findings from the registrational Phase 2 PATHFINDER study evaluating lead KIT inhibitor AYVAKIT in advanced systemic mastocytosis that showed a 75% ORR with all responses ongoing. "Encouragingly," patients responded well to therapy even after receiving any prior therapy and responses appeared to deepen with time after a quick median time of 2 months to response, Moussatos adds.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$92.68 /

-1.73 (-1.83%)

BPMC Blueprint Medicines
$92.68 /

-1.73 (-1.83%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$92.68 /

-1.73 (-1.83%)

Over a month ago
Conference/Events
Blueprint Medicines to host conference call » 07:55
04/12/21
04/12
07:55
04/12/21
07:55
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Management reviews new…

Management reviews new data for multiple research and clinical-stage programs across the Company's precision oncology and hematology portfolio on a conference call to be held on April 12 at 8 am. Webcast Link

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Conference/Events
Blueprint Medicines to host conference call » 04:55
04/12/21
04/12
04:55
04/12/21
04:55
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Management reviews new…

Management reviews new data for multiple research and clinical-stage programs across the Company's precision oncology and hematology portfolio on a conference call to be held on April 12 at 8 am. Webcast Link

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Hot Stocks
Blueprint presents data from registrational PATHFINDER trial of AYVAKIT » 18:09
04/11/21
04/11
18:09
04/11/21
18:09
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Blueprint Medicines…

Blueprint Medicines announced that multiple presentations across the company's leading systemic mastocytosis program were reported at the virtual American Association for Cancer Research Annual Meeting 2021. The presentations focused on registrational PATHFINDER trial data of AYVAKIT in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders. In a pre-specified interim analysis from the PATHFINDER trial, 32 patients who primarily received a starting dose of 200 mg once daily were evaluable for response, as of a data cutoff date of June 23, 2020. Combined with Phase 1 EXPLORER trial results, these data support Blueprint Medicines' marketing applications in advanced SM under review in the U.S. and Europe. Overall, 75 percent of patients had a confirmed response, which was defined as complete remission with full or partial recovery of peripheral blood counts, partial remission or clinical improvement. The median time to response was two months, and all responses were ongoing at a median follow-up of 10.4 months. The CRh rate was 19 percent, with a median time to CRh of 5.6 months. These results show that responses deepened over time at a rate consistent with the EXPLORER trial. The company said that AYVAKIT led to robust and durable benefits across a number of additional clinical activity measures. In new patient-reported outcomes data, AYVAKIT showed a statistically significant reduction in total symptom score after 40 weeks, as measured by the Advanced Systemic Mastocytosis Symptom Assessment Form. Treatment with AYVAKIT resulted in robust improvements in patient-reported quality of life, based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Across multiple measures of mast cell burden, AYVAKIT showed profound reductions in serum tryptase, bone marrow mast cells, KIT D816V allele burden and spleen volume. Consistent with previously disclosed data, AYVAKIT was generally well-tolerated in 62 patients enrolled in the PATHFINDER trial, and most adverse events were reported as Grade 1 or 2. The most common AEs were peripheral edema, periorbital edema, thrombocytopenia, anemia, neutropenia, diarrhea, nausea, vomiting and fatigue. Three patients discontinued AYVAKIT due to treatment-related AEs, and most patients have remained on treatment as of the data cutoff date. In non-advanced SM, skin symptoms frequently persist and can severely impact quality of life. To assess the effects of AYVAKIT on mast cell burden in skin lesions, skin biopsies were obtained at baseline and week 12 in Part 1 of the PIONEER trial. Immunohistochemistry tests were performed to determine the proportion of aberrant mast cells in skin tissue, based on expression of CD25, CD30 and other transmembrane receptors observed in SM. Skin lesional tissue at baseline had more CD30-positive than CD25-positive mast cells. Following 12 weeks of treatment, AYVAKIT significantly reduced the proportion of aberrant CD30-positive mast cells in skin lesions compared to placebo, as of a data cutoff date of December 4, 2020. These data expand on previously reported results showing the impact of AYVAKIT on skin manifestations of SM, and suggest that CD30 may be an important biomarker of aberrant mast cells in SM-related skin lesions. A placebo-controlled, Phase 1 trial evaluated the safety, tolerability and pharmacokinetics of BLU-263 in healthy volunteers. This AACR presentation reported on single ascending dose cohorts and multiple ascending dose cohorts, as of a data cutoff date of November 9, 2020. BLU-263 was well-tolerated across all doses studied, and all AEs were reported as Grade 1. Pharmacokinetic data showed dose-dependent increases in systemic exposure of BLU-263, with the half-life of BLU-263 supporting once-daily dosing. Based on these results, the company plans to evaluate BLU-263 at doses ranging from 25 to 100 mg once daily in Part 1 of the Phase 2/3 HARBOR trial in patients with non-advanced SM, which the company plans to initiate in mid-2021.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Hot Stocks
Blueprint presents preclinical data on broad precision therapy research pipeline » 16:53
04/11/21
04/11
16:53
04/11/21
16:53
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Blueprint Medicines…

Blueprint Medicines announced data from multiple poster presentations highlighting the breadth of the company's precision therapy pipeline at the virtual American Association for Cancer Research Annual Meeting 2021. Collectively, the presentations, including foundational preclinical data for multiple programs, demonstrate the productivity of the company's scientific platform.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Conference/Events
Blueprint Medicines to host conference call » 16:10
04/10/21
04/10
16:10
04/10/21
16:10
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Management reviews new…

Management reviews new data for multiple research and clinical-stage programs across the Company's precision oncology and hematology portfolio on a conference call to be held on April 12 at 8 am. Webcast Link

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Recommendations
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler » 09:18
04/09/21
04/09
09:18
04/09/21
09:18
ITOS

iTeos Therapeutics

$30.06 /

-1.06 (-3.41%)

, BPMC

Blueprint Medicines

$94.08 /

+1.07 (+1.15%)

Piper Sandler analyst…

Piper Sandler analyst Christopher Raymond says the initial release this morning of data in American Association for Cancer Research late-breaking and clinical abstracts is a "win" for iTeos Therapeutics' (IOTS) anti-TIGIT antibody, EOS-448, and in-line with previously reported data for Blueprint Medicines' (BPMC) avapritinib and BLU-263. As anticipated, dose escalation data from the first--in-human Phase 1/2a study of EOS-448 were published in the AACR abstract release this morning and were in-line with expectations, Raymond tells investors in a research note. The analyst keeps an Overweight rating on iTeos with a $50 price target. The stock in premarket trading is down 7% to $28.00.

ShowHide Related Items >><<
ITOS iTeos Therapeutics
$30.06 /

-1.06 (-3.41%)

BPMC Blueprint Medicines
$94.08 /

+1.07 (+1.15%)

ITOS iTeos Therapeutics
$30.06 /

-1.06 (-3.41%)

04/05/21 Piper Sandler
Piper Sandler continues to recommend iTeos Therapeutics into data
03/25/21 Wedbush
iTeos Therapeutics price target raised to $52 from $46 at Wedbush
10/07/20 Baird
iTeos Therapeutics initiated with an Outperform at Baird
09/18/20 Piper Sandler
Piper Sandler lays out next potential takeover targets in oncology
BPMC Blueprint Medicines
$94.08 /

+1.07 (+1.15%)

03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
02/17/21 Piper Sandler
Piper says Blueprint Medicines' Q4 commercial results 'somewhat disappointing'
ITOS iTeos Therapeutics
$30.06 /

-1.06 (-3.41%)

BPMC Blueprint Medicines
$94.08 /

+1.07 (+1.15%)

  • 24
    Jul
Initiation
Blueprint Medicines initiated with a Neutral at Credit Suisse » 16:23
03/30/21
03/30
16:23
03/30/21
16:23
BPMC

Blueprint Medicines

$93.35 /

+1.1 (+1.19%)

Credit Suisse analyst…

Credit Suisse analyst Brad Canino initiated coverage of Blueprint Medicines with a Neutral rating and $100 price target. He is "less constructive than consensus" on the sales potential of Ayvakit for systemic mastocytosis, said Canino, who calls this opportunity "the leading driver of consensus total revenue forecasts and recent share price performance." The firm's survey suggests a high 60% market penetration in the advanced disease population, but only a 15% penetration in the "larger, more valuable" indolent disease population, said Canino, who notes that his 2026 revenue estimate for Blueprint is 30% below consensus.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$93.35 /

+1.1 (+1.19%)

BPMC Blueprint Medicines
$93.35 /

+1.1 (+1.19%)

03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
02/17/21 Piper Sandler
Piper says Blueprint Medicines' Q4 commercial results 'somewhat disappointing'
01/12/21 SVB Leerink
Blueprint Medicines price target raised to $127 from $121 at SVB Leerink
BPMC Blueprint Medicines
$93.35 /

+1.1 (+1.19%)

Initiation
Blueprint Medicines initiated with a Neutral at Credit Suisse » 16:05
03/30/21
03/30
16:05
03/30/21
16:05
BPMC

Blueprint Medicines

$93.49 /

+1.24 (+1.34%)

Credit Suisse initiated…

Credit Suisse initiated coverage of Blueprint Medicines with a Neutral rating and $100 price target.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$93.49 /

+1.24 (+1.34%)

BPMC Blueprint Medicines
$93.49 /

+1.24 (+1.34%)

02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
02/17/21 Piper Sandler
Piper says Blueprint Medicines' Q4 commercial results 'somewhat disappointing'
01/12/21 SVB Leerink
Blueprint Medicines price target raised to $127 from $121 at SVB Leerink
01/11/21 Piper Sandler
Blueprint Medicines update a 'mixed bag,' says Piper Sandler
BPMC Blueprint Medicines
$93.49 /

+1.24 (+1.34%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.